Skip to main content
Canadian Journal of Public Health = Revue Canadienne de Santé Publique logoLink to Canadian Journal of Public Health = Revue Canadienne de Santé Publique
. 2004 Mar 1;95(2):104–109. doi: 10.1007/BF03405776

Client Retention in the British Columbia Methadone Program, 1996–1999

John F Anderson 15,35,, Leanne D Warren 25
PMCID: PMC6975569  PMID: 15074899

Abstract

Background

Methadone treatment for heroin addiction has been available for 40 years, but there is relatively little research on the effectiveness of Canadian programs. This paper describes one-year retention among the client cohorts entering the British Columbia Methadone Program during expansion between 1996 and 1999, and examines some factors previously shown to influence retention.

Methods

All methadone maintenance prescriptions dispensed to 1996–1999 program entrants were extracted from records of the BC Triplicate Prescription Program. Retention status and covariates were evaluated one year post-entry using logistic regression. Effects of retention status misclassification on time in the program were assessed with a Cox model for clients who received continuous daily dosing or short carries.

Results

Fifty-two percent of program entrants were still receiving methadone one year after entry; 24% had left the program at one year but later returned. Age at program entry and average daily dose of methadone were important predictors of continuation. In the logistic regression, only the 1999 year-of-entry cohort appeared to have a different retention trajectory. Year of entry is not a significant predictor of time in the program for those receiving daily or short carry doses only, and other results are consistent between models.

Interpretation

Retention rates in the BC Methadone Program are favourable and consistent with published rates. Program expansion does not reduce retention, once the effects of client age and dose are accounted for. Adequate daily dosing appears crucial to both initial retention and return to treatment.

Footnotes

Disclaimer: No financial support was received for this study. The opinions and conclusions expressed are those of the authors and do not reflect the position of the Government of British Columbia, the British Columbia College of Physicians and Surgeons, or the University of British Columbia.

References

  • 1.Lehman F, Lauzon P, Amsel R. Methadone maintenance: Predictors of outcome in a Canadian milieu. J Subst Abuse Treat. 1993;10(1):85–89. doi: 10.1016/0740-5472(93)90104-A. [DOI] [PubMed] [Google Scholar]
  • 2.Fischer B, Gliksman L, Rehm J, Daniel N, Medved W. Comparing opiate users in methadone treatment with untreated opiate users: Results of a follow-up study with a Toronto opiate user cohort. Can J Public Health. 1999;90(5):299–303. doi: 10.1007/BF03404513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Brands B, Blake J, Marsh D. Changing patient characteristics with increased methadone availability. Drug Alcohol Depend. 2002;66:11–20. doi: 10.1016/S0376-8716(01)00176-4. [DOI] [PubMed] [Google Scholar]
  • 4.The Council of the College of PhysiciansSurgeons of British Columbia. 2001 Annual Report. 2001. [Google Scholar]
  • 5.National Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–43. doi: 10.1001/jama.280.22.1936. [DOI] [PubMed] [Google Scholar]
  • 6.Ward J, Mattick RP, Hall W. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. 1998. [Google Scholar]
  • 7.Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. Am J Public Health. 1998;88(1):34–39. doi: 10.2105/AJPH.88.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Magura S, Nwakeze PC, Demsky SY. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 1998;93(1):51–60. doi: 10.1046/j.1360-0443.1998.931516.x. [DOI] [PubMed] [Google Scholar]
  • 9.Gaughwin M, Solomon P, Ali R. Correlates of retention on the South Australian Methadone Program 1981–91. Austr N Z J Public Health. 1998;22(7):771–76. doi: 10.1111/j.1467-842X.1998.tb01491.x. [DOI] [PubMed] [Google Scholar]
  • 10.Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and Hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000;77(3):331–45. doi: 10.1007/BF02386744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bammer G, Battison L, Ward J, Wilson S. The impact on retention of expansion of an Australian public methadone program. Drug Alcohol Depend. 2000;58:173–80. doi: 10.1016/S0376-8716(99)00084-8. [DOI] [PubMed] [Google Scholar]
  • 12.Freedom of Information and Protection of Privacy Act (RSBC 1996, Chapter 165). Victoria: Queen’s Printer, 2003.
  • 13.Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: A metaanalysis. Drug Alcohol Depend. 2002;65:283–90. doi: 10.1016/S0376-8716(01)00171-5. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Journal of Public Health = Revue Canadienne de Santé Publique are provided here courtesy of Springer

RESOURCES